Denne side blev automatisk oversat, og nøjagtigheden af ​​oversættelsen er ikke garanteret. Der henvises til engelsk version for en kildetekst.

Serum Asprosin, Metabolic Syndrome, and Cardiometabolic Risk in Rheumatoid Arthritis

26. august 2026 opdateret af: Viola Rafaat Shafik Tadros, Assiut University

Association of Serum Asprosin With Metabolic Syndrome and Cardiometabolic Risk in Patients With Rheumatoid Arthritis

Rheumatoid arthritis (RA) is a chronic inflammatory autoimmune disease associated with a significantly increased risk of cardiovascular disease and metabolic syndrome (MetS). Asprosin is a recently identified adipokine involved in glucose regulation, insulin resistance, and systemic inflammation, but its role in the cardiometabolic complications of RA remains incompletely understood.

The purpose of this case-control study is to evaluate and compare serum Asprosin levels among RA patients with metabolic syndrome, RA patients without metabolic syndrome, and healthy control individuals. The study will also assess the association between serum Asprosin concentrations, RA disease activity (DAS28-ESR), and various cardiometabolic risk indices (including TyG index, Atherogenic Index of Plasma, and Castelli risk indices).

Participants will undergo a comprehensive clinical assessment, disease activity scoring, physical function evaluation using the Health Assessment Questionnaire (HAQ), and laboratory investigations including fasting blood tests and serum Asprosin measurement via ELISA. Findings from this study may help clarify the pathophysiological role of Asprosin in RA and improve cardiometabolic risk stratification in affected patients.

Studieoversigt

Status

Ikke rekrutterer endnu

Betingelser

Undersøgelsestype

Observationel

Tilmelding (Anslået)

75

Deltagelseskriterier

Forskere leder efter personer, der passer til en bestemt beskrivelse, kaldet berettigelseskriterier. Nogle eksempler på disse kriterier er en persons generelle helbredstilstand eller tidligere behandlinger.

Berettigelseskriterier

Aldre berettiget til at studere

  • Voksen
  • Ældre voksen

Tager imod sunde frivillige

N/A

Prøveudtagningsmetode

Ikke-sandsynlighedsprøve

Studiebefolkning

Adult patients aged 18 years and older diagnosed with rheumatoid arthritis fulfilling the 2010 ACR/EULAR classification criteria, recruited from the inpatient and outpatient clinics of the Rheumatology, Rehabilitation, and Physical Medicine Department at Assiut University Hospital, along with age- and sex-matched healthy control individuals.

Beskrivelse

Inclusion Criteria:

  • Adult patients aged 18 years or older.
  • Diagnosis of rheumatoid arthritis fulfilling the 2010 ACR/EULAR classification criteria.
  • Ability and willingness to provide written informed consent.
  • Healthy controls: Age- and sex-matched individuals without rheumatoid arthritis or systemic inflammatory diseases.

Exclusion Criteria:

  • Presence of other autoimmune diseases or overlap syndromes.
  • Active acute or chronic infectious diseases.
  • Pregnancy or lactation.
  • Current malignancy or previous history of malignancy.
  • Severe hepatic or renal impairment.
  • Receipt of medications primarily prescribed for weight reduction or agents known to markedly alter lipid or glucose metabolism, other than standard rheumatoid arthritis therapy.

Studieplan

Dette afsnit indeholder detaljer om studieplanen, herunder hvordan undersøgelsen er designet, og hvad undersøgelsen måler.

Hvordan er undersøgelsen tilrettelagt?

Design detaljer

Kohorter og interventioner

Gruppe / kohorte
Rheumatoid Arthritis with Metabolic Syndrome
Adult patients diagnosed with rheumatoid arthritis fulfilling the 2010 ACR/EULAR classification criteria who also meet the NCEP ATP III criteria for metabolic syndrome (presence of 3 or more metabolic components). Serum Asprosin levels and cardiometabolic risk indices will be evaluated.
Rheumatoid Arthritis without Metabolic Syndrome
Adult patients diagnosed with rheumatoid arthritis fulfilling the 2010 ACR/EULAR classification criteria who do not meet the NCEP ATP III diagnostic criteria for metabolic syndrome. Serum Asprosin levels and cardiometabolic risk indices will be evaluated.
Healthy Controls
Age- and sex-matched healthy control individuals without rheumatoid arthritis, metabolic syndrome, or systemic inflammatory conditions, recruited for comparative assessment of baseline serum Asprosin levels.

Hvad måler undersøgelsen?

Primære resultatmål

Resultatmål
Foranstaltningsbeskrivelse
Tidsramme
Serum Asprosin Level
Tidsramme: Baseline
Serum asprosin concentration (measured in ng/mL) assessed via a commercial enzyme-linked immunosorbent assay (ELISA) kit to compare rheumatoid arthritis patients with metabolic syndrome versus rheumatoid arthritis patients without metabolic syndrome.
Baseline

Samarbejdspartnere og efterforskere

Det er her, du vil finde personer og organisationer, der er involveret i denne undersøgelse.

Sponsor

Assiut University

Datoer for undersøgelser

Disse datoer sporer fremskridtene for indsendelser af undersøgelsesrekord og resumeresultater til ClinicalTrials.gov. Studieregistreringer og rapporterede resultater gennemgås af National Library of Medicine (NLM) for at sikre, at de opfylder specifikke kvalitetskontrolstandarder, før de offentliggøres på den offentlige hjemmeside.

Studer store datoer

Studiestart (Anslået)

1. oktober 2026

Primær færdiggørelse (Anslået)

1. oktober 2027

Studieafslutning (Anslået)

1. november 2027

Datoer for studieregistrering

Først indsendt

26. august 2026

Først indsendt, der opfyldte QC-kriterier

26. august 2026

Først opslået (Faktiske)

31. august 2026

Opdateringer af undersøgelsesjournaler

Sidste opdatering sendt (Faktiske)

31. august 2026

Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier

26. august 2026

Sidst verificeret

1. august 2026

Mere information

Begreber relateret til denne undersøgelse

Nøgleord

Yderligere relevante MeSH-vilkår

Andre undersøgelses-id-numre

  • Asprosin in RA & MetS Risk

Disse oplysninger blev hentet direkte fra webstedet clinicaltrials.gov uden ændringer. Hvis du har nogen anmodninger om at ændre, fjerne eller opdatere dine undersøgelsesoplysninger, bedes du kontakte register@clinicaltrials.gov. Så snart en ændring er implementeret på clinicaltrials.gov, vil denne også blive opdateret automatisk på vores hjemmeside .

Abonner